Royal Sense P/E Ratio
Current P/E Ratio
4.8
Low Valuation
Very Low - Potentially undervalued or facing challenges
Royal Sense P/E ratio. Royal Sense (ROYAL) P/E ratio is 4.8 (Low), EPS (TTM) ₹13.46, current price ₹ on None — Very Low - Potentially undervalued or facing challenges. Check ROYAL market value to track the company's total market size over time.
Current Valuation Metrics
P/E Ratio
4.8
Current Price
₹
EPS (TTM)
₹13.46
Exchange
None
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
52.38
Sector Median
29.6
Sector Rank
#8 of 255
Sector Percentile
3.1%
ROYAL P/E Ratio — Valuation Signal & Historical Context
Royal Sense P/E 4.8 — signal: Undervalued. Also explore Royal Sense share price performance to track price trends across different timeframes.
- Stock appears undervalued with PE of 4.8, suggesting potential buying opportunity
- Trading at discount to sector average PE of 52.38
ROYAL vs Healthcare Peers — P/E Ratio Comparison
Royal Sense P/E 4.8 vs Healthcare average 52.38, median 29.6 — range 2.0–733.0.
Sector Average
52.38
Sector Median
29.6
Lowest P/E
2.0
Highest P/E
733.0
Companies
255
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |
| Colinz Laboratories | COLINZ | 6.5 | ₹17 | Low |